Hippo buys back $14.5M in common stock held by Lennar
On June 11, 2025, Hippo Holdings (HIPO) entered into an agreement with certain entities affiliated with LEN FW Investor, LLC whereby the Company agreed to repurchase 514,309 shares of its common stock, par value $0.0001 per share, beneficially owned by Lennar in a private transaction at a price per Share of $28.17, for an aggregate purchase price of $14.5 million. The repurchase of the Shares pursuant to the Share Repurchase Agreement will be made under the Company's existing share repurchase program. As of June 16, 2025, after giving effect to the repurchase of the Shares pursuant to the Share Repurchase Agreement, approximately $18.1 million of authorization remains available under the share repurchase program. The Share Repurchase Agreement contains customary representations, warranties, and covenants of the parties. The transaction is expected to close in the third quarter of 2025.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Stearman Enters Into Definitive Agreement to Acquire NeoCore Uranium Ltd.
VANCOUVER, British Columbia, June 17, 2025 (GLOBE NEWSWIRE) — Stearman Resources Inc. (CSE:STMN) ('Stearman' or the 'Company') announces that it has entered into a definitive share exchange agreement ('NeoCore Agreement') to acquire 100% of the issued and outstanding common shares of NeoCore Uranium Ltd. ('NeoCore'), a private BC company that owns a 100% interest in the NeoCore Uranium Property ('Property'). The Property consists of six mineral claims covering 13,012 hectares, located in the Athabasca Basin in northern Saskatchewan. The Property is located on the eastern flank of the Athabasca Basin, about 65 kilometres southeast of the McArthur River Uranium Mine. It is underlain by Neoarchean River Granites, a geologic unit associated with uranium fertility in both Canadian and global analogs. The Property area is directly adjacent to renowned uranium mining and exploration companies including CanAlaska Uranium Ltd., Skyharbour Resources Ltd. and Baselode Energy Corp. The NeoCore Agreement provides for Stearman to issue 7,500,000 common shares in the capital of the Company (each, a 'Company Share'), at a deemed price of $0.05 per share, in exchange for all the issued and outstanding common shares (the 'NeoCore Shares') of NeoCore (the 'Transaction'). The Company expects to close the Transaction on or before June 30, 2025. The Transaction is subject to certain terms and conditions, including the completion of customary due diligence, the receipt of all required regulatory approval and completion of the Financing (as defined below). There can be no guarantee that the Transaction will be completed as contemplated or at all. The Transaction is at arm's length and there are no finder's fees payable in connection therewith. The Company also announces a non-brokered private placement financing of 2,000,000 units (each, a 'Unit') at a price of $0.05 per Unit for gross proceeds of $100,000 (the 'Financing'). Each Unit will consist of one Company Share and one transferrable common share purchase warrant entitling the holder to purchase one additional Company Share for $0.07 for a period of two years. The net proceeds from the Financing will be used for general corporate purposes. All securities issued pursuant to the Transaction and the Financing will be subject to a hold period of four months and one day as required under applicable securities legislation. After closing the Transaction, the Company plans to file a Business Acquisition Report ('BAR') in accordance with securities regulations within the prescribed time with respect to the acquisition, and it will issue a further news release on filing the BAR. The Company is a mineral exploration company focused on the acquisition, exploration and development of mineral properties in Canada and the USA. The Company currently has an option on the Miniac Property in Quebec, which consists of 78 claims over 4,110 hectares located 35 kilometres north of Amos, Quebec, prospective for gold, zinc, copper and silver, and an option on the Brassie Creek Property, consisting of 9 mineral claims covering 1,862 hectares, located 48 kilometres west of Kamloops, BC, prospective for copper, gold and silver. On Behalf of the Company Howard Milne, Chief Executive Officer For further information, please contact Howard Milne, CEO at 604-377-8994 email hdmcap@ Forward Looking Statements: This press release may contain 'forward‐looking information or statements' within the meaning of Canadian securities laws, which may include, but are not limited to statements relating to its future business plans. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ from those in the forward-looking statements. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law. The CSE has neither approved nor disapproved the contents of this press release. Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.
Business Insider
3 hours ago
- Business Insider
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the 'Company'), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'RAPT' with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a reverse stock split-adjusted basis on June 17, 2025. At the effective time of the reverse split, every eight issued and outstanding shares of the Company's common stock will automatically be combined into one issued and outstanding share of the Company's common stock without any change in the par value per share. Fractional shares will not be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to receive a cash payment. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares. The reverse stock split will not affect the absolute number of the Company's authorized shares of common stock, which will remain at 500,000,000, but the total number of authorized shares of the Company's common stock available for future issuance will increase. In addition, proportionate adjustments will be made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding pre-funded warrants and stock options, and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 132.3 million to approximately 16.5 million. RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'will' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the reverse stock split and the timing thereof, the impact of the reverse stock split on stockholders, including any adjustments that may result from the treatment of fractional shares, pre-funded warrant holders and option holders, the potential impact of the reverse stock split on the bid price of the Company's common stock, the expected number of shares of common stock to be issued and outstanding following the reverse stock split, and other statements that are not historical fact. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
Business Wire
4 hours ago
- Business Wire
Faraday Future Announces Additional Senior Leadership Entering Into 10b5-1 Stock Purchase Plans
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or the 'Company'), a California-based global shared intelligent electric mobility ecosystem company, today announced that a number of its senior leadership have entered into 10b5-1 executive stock purchase plans. Under SEC compliance rules, there will be either a 45 or 90-day cooling-off period, after which their broker will automatically execute the stock purchases at times and in amounts in accordance with the plans. A combined total of $60,000 worth of share purchase commitments for FF common stock (including commission fee) were made by various members of FF's leadership team, including Koti Meka, FF CFO, Xiao (Max) Ma, FX brand CEO and Dr. Lei Gu, President of FX Global EV R&D Center. The 10b5-1 plans were officially initiated on June 13, 2025. 'These planned stock purchases reflect the continued confidence by members of FF's core leadership team and serve as a positive indicator by all of them in FF's long-term vision and commitment to our mission and products,' said YT Jia, FF Founder and Global Co-CEO. 'This is yet another demonstration of our core principle: Stockholders First.' ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'plan to,' 'can,' 'will,' 'should,' 'future,' 'potential,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding 10b5-1 purchase plans, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: each executive's ability to cancel or amend his 10b5-1 purchase plan; potential volume limitations under Rule 144 or Rule 145 of the Securities Act of 1933, as amended, or Regulation M; the possible suspension of purchases due to a trading suspension, legal, regulatory or contractual restrictions; or a subsequent determination that a 10b5-1 plan does not comply with Rule 10b5-1 or other applicable securities laws. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
